Back to search

Article

Cyclophosphamide pharmacogenomics and their effect on its bioactivation and pharmacokinetics

2023-08-18

Abstract excerpt

Cyclophosphamide (Cy) is a prodrug that is mainly bioactivated by the cytochrome enzyme CYP2B6. Several other enzymes are also involved in its bioactivation and affect its kinetics. Previous studies have shown the effect of the enzymes’ genetic polymorphisms on Cy kinetics and its clinical outcome. These results were controversial primarily because of the involvement of several interacting enzymes in the Cy metabo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0963b0a0-7e5b-5ea8-ac70-0f308d079608
DOI
10.22541/au.169232953.37091454/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Cyclophosphamide pharmacogenomics and their effect on its bioactivation and pharmacokineticsDOI 10.22541/au.169232953.37091454/v1
The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomesSemantic proximity
Role of Pharmacogenetics in Busulfan/Cyclophosphamide Conditioning Therapy Prior to Hematopoietic Stem Cell TransplantationSemantic proximity
The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.Semantic proximity
Influence of Genetic Variation of GST, CYP, and ABC on the Safety and Efficacy of Cyclophosphamide-Based Therapy.Semantic proximity
Pharmacogenetic aspects of drug metabolizing enzymes in busulfan based conditioning prior to allogenic hematopoietic stem cell transplantation in children.Semantic proximity
Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.Semantic proximity
Association of ALDH1A1 Polymorphism With Toxicity From Cyclophosphamide TreatmentSemantic proximity
Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastomaSemantic proximity
Activation/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer TherapySemantic proximity
Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation.Semantic proximity
Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantationSemantic proximity
CYP2B6 genetic variation in cyclophosphamide metabolism and hemorrhagic cystitis in Fanconi anemia patients undergoing allogeneic hematopoietic cell transplantationSemantic proximity
Select a neighboring publication to make it the new centre.